CNCR vs. HTUS

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and HTUS (Hull Tactical US ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while HTUS is a Long-Short fund actively managed by Exchange Traded Concepts. CNCR is passively managed, while HTUS is actively managed. CNCR charges 0.79%/yr vs 0.97%/yr for HTUS.

Performance

CNCR vs. HTUS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Hull Tactical US ETF (HTUS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

HTUS

• 1D: 0.24%
• 1M: 5.23%
• YTD: 11.94%
• 6M: 13.14%
• 1Y: 30.10%
• 3Y*: 22.37%
• 5Y*: 15.60%
• 10Y*: 12.59%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. HTUS - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
HTUS Hull Tactical US ETF	10.68%

CNCR vs. HTUS - Sectors Allocation Comparison

Sectors	CNCR	HTUS
Healthcare	96.6%	8.5%
Financial Services	3.3%	11.8%
Basic Materials	-	1.8%
Communication Services	-	11.2%
Consumer Cyclical	-	10.1%
Consumer Defensive	-	4.9%
Energy	-	3.5%
Industrials	-	8.3%
Real Estate	-	1.9%
Technology	-	35.6%
Utilities	-	2.4%

Return for Risk

CNCR vs. HTUS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HTUS

HTUS Risk / Return Rank: 81
HTUS Sharpe Ratio Rank: 80
HTUS Sortino Ratio Rank: 85
HTUS Omega Ratio Rank: 85
HTUS Calmar Ratio Rank: 68
HTUS Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. HTUS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Hull Tactical US ETF (HTUS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	HTUS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.63	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.82	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.59	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.58	—

Drawdowns

CNCR vs. HTUS - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum HTUS drawdown of -47.50%. Use the drawdown chart below to compare losses from any high point for CNCR and HTUS.

Drawdown Indicators

	CNCR	HTUS	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-47.50%	+47.50%
Max Drawdown (1Y) Largest decline over 1 year	—	-8.68%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-24.41%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-24.41%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-47.50%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-4.06%	+4.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	1.68%	—

Volatility

Volatility by Period

	CNCR	HTUS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	2.42%	—
Volatility (6M) Calculated over the trailing 6-month period	—	9.40%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	11.49%	-11.49%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	19.03%	-19.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	21.45%	-21.45%

CNCR vs. HTUS - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than HTUS's 0.97% expense ratio.

Dividends

CNCR vs. HTUS - Dividend Comparison

CNCR has not paid dividends to shareholders, while HTUS's dividend yield for the trailing twelve months is around 10.62%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
HTUS Hull Tactical US ETF	10.62%	11.89%	17.80%	1.18%	5.63%	7.20%	3.77%	0.92%	8.69%	8.29%	3.02%

Frequently Asked Questions

Which ETF is better, CNCR or HTUS?

On fees, CNCR is cheaper at 0.79% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or HTUS?

CNCR is cheaper with a 0.79% expense ratio, compared with 0.97% for HTUS.

Which ETF pays a higher dividend yield, CNCR or HTUS?

HTUS has the higher dividend yield at 10.62%, compared with 0.00% for CNCR.

What is the main difference between CNCR and HTUS?

CNCR is categorized as Health & Biotech Equities, while HTUS is Long-Short. Their fees differ too: 0.79% for CNCR and 0.97% for HTUS.